X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The transaction will enhance UCB’s potential to be a leader in myasthenia gravis by adding zilucoplan, currently in phase 3, to the UCB pipeline alongside rozanolixizumab.
Lead Product(s): Zilucoplan
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: UCB Pharma S.A
Deal Size: $2,300.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition April 02, 2020
Details:
the study demonstrated that zilucoplan resulted in rapid, clinically meaningful, statistically significant, and sustained improvements in the primary and key secondary endpoints.
Lead Product(s): Zilucoplan
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2020
Details:
Zilucoplan was selected as one of the first clinical candidates to be evaluated in this platform trial for ALS led by the Sean M. Healey & AMG Center for ALS at Mass General.
Lead Product(s): Zilucoplan
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
